A5047354068- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- COVID-19 Clinical Research Studies
- COVID-19 and healthcare impacts
- COVID-19 epidemiological studies
- Viral gastroenteritis research and epidemiology
- Antibiotic Use and Resistance
- Healthcare Systems and Public Health
- Pneumonia and Respiratory Infections
- Nosocomial Infections in ICU
- Migration, Health and Trauma
- Influenza Virus Research Studies
- SARS-CoV-2 detection and testing
Istituto Superiore di Sanità
2021-2023
Effectiveness against severe COVID-19 of a second booster dose the bivalent (original/BA.4-5) mRNA vaccine 7-90 days post-administration, relative to first an received ≥ 120 earlier, was ca 60% both in persons 60 years never infected and those > 6 months before. Relative effectiveness 4-6 earlier indicated no significant additional protection (10%; 95% CI: -44 44). A vaccination after latest infection may be warranted.
We explored the risk factors associated with SARS-CoV-2 reinfections in Italy between August 2021 and March 2022. Regardless of prevalent virus variant, being unvaccinated was most relevant factor for reinfection. The reinfection increased almost 18-fold following emergence Omicron variant compared Delta. A severe first infection age over 60 years were significant
We assessed the impact of COVID-19 vaccination in Italy, by estimating numbers averted cases, hospitalisations, ICU admissions and deaths between January September 2021, age group geographical macro areas. Timing speed programme implementation varied slightly areas, particularly for older adults. estimated that 445,193 (17% expected; range: 331,059-616,054) 79,152 (32%; 53,209-148,756) 9,839 (29%; 6,434-16,276) 22,067 (38%; 13,571-48,026) were prevented vaccination.
Protein recombinant vaccine NVX-CoV2373 (Novavax) against COVID-19 was authorized for its use in adults late 2021, but evidence on estimated effectiveness a general population is lacking.To estimate of primary cycle with SARS-CoV-2 infection and symptomatic COVID-19.Retrospective cohort study linking data from the national vaccination registry surveillance system Italy during period Omicron predominance. All starting between February 28 September 4, 2022, were included, follow-up ending 25,...
Several countries started a 2nd booster COVID-19 vaccination campaign targeting the elderly population, but evidence around its effectiveness is still scarce. This study aims to estimate relative of dose mRNA vaccine in population aged ≥ 80 years Italy, during predominant circulation Omicron BA.2 and BA.5 subvariants. We linked routine data from national registry surveillance system. On each day between 11 April 6 August 2022, we matched 1:1, according several demographic clinical...
Consolidated information on the effectiveness of COVID-19 booster vaccination in Europe are scarce.We assessed a dose an mRNA vaccine against any SARS-CoV-2 infection (symptomatic or asymptomatic) and severe (hospitalization death) after over two months from administration among priority target groups (n = 18,524,568) during predominant circulation Delta variant Italy (July-December 2021).Vaccine (VE) and, to lesser extent, COVID-19, people ≥60 years other high-risk (i.e. healthcare workers,...
This study was to compare the incidence and clinical outcomes of SARS-CoV-2 infection between Italian non-Italian nationals.We retrospectively analysed data from COVID-19 integrated surveillance system (14 September 2020 17 October 2021).We used multivariable Cox proportional hazards models estimate hazard ratio (HR) and, among cases, HRs death, hospitalisation subsequent admission intensive care unit in nationals relative nationals. Estimates were adjusted for differences sociodemographic...
Coronavirus disease 19 (COVID-19) is an infectious caused by the Severe Acute Respiratory Syndrome 2 (SARS-CoV-2). To date, few data on clinical features and risk factors for severity death gender are available.The current study aims to describe from a sex/gender perspective characteristics of SARS-CoV-2 cases occurred in Italian population February 2020 until October 2021.We used routinely collected retrieved National Surveillance System. The highest number among women between 40 59 years,...